Takeda’s Oral TYK2 Inhibitor Zasocitinib Delivers Strong Phase 3 Psoriasis Results

Takeda Pharmaceutical Co ( (JP:4502) ) just unveiled an update.

Takeda reported positive topline results from two pivotal Phase 3 trials of zasocitinib (TAK-279), a once-daily, highly selective oral TYK2 inhibitor, in adults with moderate-to-severe plaque psoriasis, where the drug met all primary and 44 ranked secondary endpoints and showed superiority to placebo and the active comparator apremilast on key skin clearance measures. More than half of treated patients achieved clear or almost clear skin (PASI 90) and about 30% achieved completely clear skin (PASI 100) by week 16 with a safety profile consistent with prior studies, reinforcing zasocitinib’s potential as a leading oral psoriasis therapy; Takeda plans regulatory submissions starting in fiscal 2026 and is extending development of the drug into psoriatic arthritis, inflammatory bowel disease and other indications, although the Phase 3 results are not expected to affect its current full-year financial forecast.

The most recent analyst rating on (JP:4502) stock is a Hold with a Yen4898.00 price target. To see the full list of analyst forecasts on Takeda Pharmaceutical Co stock, see the JP:4502 Stock Forecast page.

More about Takeda Pharmaceutical Co

Takeda Pharmaceutical Co. is a global biopharmaceutical company headquartered in Japan with significant operations in the U.S., focusing on innovative therapies across areas such as gastroenterology, immunology and rare diseases. Its pipeline includes next‑generation small molecules and biologics, with an emphasis on immune‑mediated conditions and other serious chronic diseases where there is high unmet medical need.

Average Trading Volume: 4,472,461

Technical Sentiment Signal: Strong Buy

Current Market Cap: Yen7160.9B

Learn more about 4502 stock on TipRanks’ Stock Analysis page.